Regression of nevi in a melanoma patient treated with interferon
Keywords:
regression, nevi, interferon alpha2bReferences
1. Kirkwood JM, Ibrahim JG, Sondak VK, Ernstoff MS, Ross M. Interferon alfa-2a for melanoma metastases. Lancet. 2002;359(9310):978-9.
2. Wheatley K, Hancock B, Gore M, Suciu S, Eggermont A. Interferon-alpha as adjuvant therapy for melanoma: a meta-analysis of the randomised trials. Proc Am Soc Clin Oncol. 2001;20:1394.
3. Rajadhyaksha M, Grossman M, Esterowitz D, Webb RH, Anderson RR. In vivo confocal scanning laser microscopy of human skin: melanin provides strongcontrast. J Invest Dermatol. 1995;104(6):946-52.
4 . Gonzalez S, Gill M, Halpern AC. Reflectance Confocal Microscopy of Cutaneous Tumors: An Atlas With Clinical, Dermoscopic and Histological Correlations. New York, NY: Informa HealthCare, 2008:30-75.
5. Byrne KT, Turk MJ. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget. 2011;2(9):684-94.
6. Zeff RA, Freitag A, Grin CM, Grant-Kels JM. The immune response in halo nevi. J Am Acad Dermatol. 1997;37(4):620-4.
7. Hu S, Kim CC, Jessup C, Phung TL, Curiel-Lewandrowski C. Primary cutaneous melanomas seen as inflamed pigmented lesions in patients undergoing adjuvant interferon treatment: a possible diagnostic clue for physicians. Arch Dermatol. 2009;145(5):565-8. CrossRef
8. Dusza SW, Delgado R, Busam KJ, Marghoob AA, Halpern AC. Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study. J Drugs Dermatol. 2006;5(1):56-62.
9. Somani N, Martinka M, Crawford RI, Dutz JP, Rivers JK. Treatment of atypical nevi with imiquimod 5% cream. Arch Dermatol. 2007;143(3):379-85.
2. Wheatley K, Hancock B, Gore M, Suciu S, Eggermont A. Interferon-alpha as adjuvant therapy for melanoma: a meta-analysis of the randomised trials. Proc Am Soc Clin Oncol. 2001;20:1394.
3. Rajadhyaksha M, Grossman M, Esterowitz D, Webb RH, Anderson RR. In vivo confocal scanning laser microscopy of human skin: melanin provides strongcontrast. J Invest Dermatol. 1995;104(6):946-52.
4 . Gonzalez S, Gill M, Halpern AC. Reflectance Confocal Microscopy of Cutaneous Tumors: An Atlas With Clinical, Dermoscopic and Histological Correlations. New York, NY: Informa HealthCare, 2008:30-75.
5. Byrne KT, Turk MJ. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget. 2011;2(9):684-94.
6. Zeff RA, Freitag A, Grin CM, Grant-Kels JM. The immune response in halo nevi. J Am Acad Dermatol. 1997;37(4):620-4.
7. Hu S, Kim CC, Jessup C, Phung TL, Curiel-Lewandrowski C. Primary cutaneous melanomas seen as inflamed pigmented lesions in patients undergoing adjuvant interferon treatment: a possible diagnostic clue for physicians. Arch Dermatol. 2009;145(5):565-8. CrossRef
8. Dusza SW, Delgado R, Busam KJ, Marghoob AA, Halpern AC. Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study. J Drugs Dermatol. 2006;5(1):56-62.
9. Somani N, Martinka M, Crawford RI, Dutz JP, Rivers JK. Treatment of atypical nevi with imiquimod 5% cream. Arch Dermatol. 2007;143(3):379-85.
Downloads
Published
2012-04-30
Issue
Section
Observation
License
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
1.
Rishpon A, Nathanson N. Regression of nevi in a melanoma patient treated with interferon. Dermatol Pract Concept. Published online April 30, 2012:27-30. doi:10.5826/dpc.0202a07
Share
